Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from BTIG Research

BTIG Research reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Thursday morning,Benzinga reports. BTIG Research currently has a $39.00 price target on the stock.

A number of other research analysts have also recently issued reports on STOK. Canaccord Genuity Group boosted their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Wedbush raised their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday. Guggenheim initiated coverage on Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective on the stock. Needham & Company LLC boosted their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.83.

Stoke Therapeutics Stock Up 7.0%

Shares of STOK stock opened at $33.19 on Thursday. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $40.22. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. The firm has a fifty day moving average of $32.60 and a 200-day moving average of $29.93.

Insider Activity

In other news, insider Barry Ticho sold 6,686 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24. Following the completion of the transaction, the insider directly owned 40,798 shares of the company’s stock, valued at $1,278,609.32. This represents a 14.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the transaction, the general counsel owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. The trade was a 13.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 69,699 shares of company stock worth $2,526,714. 9.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of STOK. Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $26,000. Harbour Investments Inc. lifted its position in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics during the third quarter worth $41,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after purchasing an additional 658 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares in the last quarter.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms reaffirmed or raised ratings/targets this week (BTIG/BTIG-linked coverage, Wedbush to $38 and Outperform, Needham bullish) which supports upside expectations and likely attracted buying. Analyst Price Target Raises Wedbush Boosts Price Target Needham Coverage
• Positive Sentiment: Favorable coverage of lead program STK‑001 — Profiles highlighting Stoke’s experimental therapy and potential to address developmental loss in Dravet syndrome boost the story around long‑term clinical upside. FierceBiotech: STK‑001 Coverage
• Neutral Sentiment: Inducement stock options granted — The company granted 58,650 options to new hires (effective March 16), which helps recruiting but adds potential future dilution; impact is mixed and longer‑term. Inducement Grants Release
• Negative Sentiment: Quarterly results missed expectations — Stoke reported EPS and revenue below consensus (EPS narrower than expected loss and revenue well below estimates), a clear near‑term negative that can pressure the stock until visibility improves. Quarterly Earnings Report
• Negative Sentiment: Significant insider selling across multiple executives — Several insiders (including the General Counsel, CFO, other officers and a director) sold sizeable blocks over March 17–19, reducing holdings by double‑digit percentages in some cases; heavy insider sales can be interpreted as a bearish signal by some investors. Representative SEC filing: Insider Form 4
• Negative Sentiment: News pieces highlighting a price drop — Market commentary and headlines about a sudden drop can amplify selling momentum among short‑term traders. Kalkine: What Triggered This Drop?

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.